Meaningful Use and Clinical Utility of Preemptive Pharmacogenetic Testing: (Re)View From a CYP2D6 Poor Metabolizer

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 119-121

John Wiley & Sons Inc

Access to resources Recommend Favorite

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 5, 2015-11 ,pp. : 1122-1130

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Trigonella foenum-graecum L. on Metabolic Activity of CYP2D6 and CYP3A4

By  

Forschende Komplementärmedizin / Research in Complementary Medicine, Vol. 22, Iss. 3, 2015-06 ,pp. : 180-184

Karger

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 5, 2013-05 ,pp. : 402-408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

By Fleeman Nigel   Payne Katherine   Newman William G   Howell Sacha J   Boland Angela   Oyee James   Saborido Carlos Martin   Santander Ana Fernández   Dickson Rumona  

Personalized Medicine, Vol. 10, Iss. 6, 2013-08 ,pp. : 601-611

Future Medicine

Access to resources Recommend Favorite